Effect of Tanshinone on Hormonal and Metabolic Features in Women With Polycystic Ovary Syndrome (PCOS)

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-12002973

Enrollment

Unknown

Registered

2012-12-31

Start date

2012-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic Ovary Syndrome (PCOS)

Interventions

1:Tanshinone

2:placebo

Eligibility

Sex/Gender

Female

Age

18 Years to 36 Years

Inclusion criteria

Inclusion criteria: 1. Age between 18 to 36; 2. Oligo/anovulation and(or) polycystic ovary; 3. FG score over 8 or hyperandrogenimia; 4. No desire of children within one year.

Exclusion criteria

Exclusion criteria: 1. clinically significant pulmonary, cardiac, renal, hepatic, neurologic, psychiatric, infectious, neoplastic and malignant disease; 2. Current use of oral contraceptives;

Design outcomes

Primary

Measure	Time frame
Hormone level;	—

Contacts

Public ContactXiaoke Wu

xiaokewu2002@vip.sina.com+86 13796025599

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 10, 2026